1. Clonal selection of high producing, stably transfected HEK293 cell lines utilizing modified, high-throughput FACS screening
- Author
-
Peter P. Gray, David Y. Chin, Michael Song, Martina L. Jones, Kristin Raphaelli, Stephen M. Mahler, Khosrow Aliabadi-Zadeh, Kar Man Leung, Edwin P. Huang, David Crowley, and Benjamin S. Hughes
- Subjects
biology ,medicine.diagnostic_test ,Renewable Energy, Sustainability and the Environment ,medicine.drug_class ,General Chemical Engineering ,Chinese hamster ovary cell ,Organic Chemistry ,Transfection ,Monoclonal antibody ,Pollution ,Molecular biology ,Hydrolysate ,Flow cytometry ,law.invention ,Inorganic Chemistry ,Fuel Technology ,law ,biology.protein ,medicine ,Recombinant DNA ,Antibody ,Clone (B-cell biology) ,Waste Management and Disposal ,Biotechnology - Abstract
BACKGROUND: Human embryonic kidney-293 (HEK-293) cells are commonly used as a transient expression host but their application in stable therapeutic protein production is limited. This is presumably due to the absence of a suitable amplifiable expression system and hence limited protein output compared with other mammalian cells such as Chinese hamster ovary cells. This paper describes a rapid clonal selection method for isolating HEK293 cell lines with high specific productivity, for a non-amplifiable expression system, to achieve high-level, scalable expression of recombinant antibodies. RESULTS: Flow cytometry utilizing cold capture of secreted protein on the cell surface was applied to isolate high expressing clones from a stable antibiotic resistant pool. The top three isolated clones showed a five- to seven-fold improvement in volumetric outputs compared with the initial resistant pool (∼20 mg L−1) under batch conditions. In fed-batch conditions using commercially available hydrolysate supplements, the final titre was further increased to 500–600 mg L−1 in shaker flasks. One clone was scaled up to 25 L bag production using a similar hydrolysate feeding regime. The antibody titre reached 655 mg L−1, and 12 g of antibody was recovered after purification, demonstrating scalability of the process. The process of clonal selection through to fed-batch production of gram quantities was completed within 4 months. CONCLUSION: HEK-293 cells can be used as a stable host for the production of biopharmaceuticals, producing gram quantities of recombinant proteins for preclinical development. Copyright © 2011 Society of Chemical Industry
- Published
- 2011
- Full Text
- View/download PDF